About Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SymbolNASDAQ:CAPRPrevious Symbol: NASDAQ:NLTX
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$4 million
Price / Sales13.50
Price / CashN/A
Book Value($0.17) per share
Price / Book-12.35
Return on EquityN/A
Return on Assets-82.11%
Frequently Asked Questions for Capricor Therapeutics (NASDAQ:CAPR)
What is Capricor Therapeutics' stock symbol?
Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."
How were Capricor Therapeutics' earnings last quarter?
Capricor Therapeutics, Inc. (NASDAQ:CAPR) released its quarterly earnings data on Wednesday, November, 8th. The biotechnology company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.07. The biotechnology company earned $0.31 million during the quarter, compared to the consensus estimate of $1 million. The business's revenue was down 58.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.29) EPS. View Capricor Therapeutics' Earnings History.
Where is Capricor Therapeutics' stock going? Where will Capricor Therapeutics' stock price be in 2017?
2 Wall Street analysts have issued 1-year target prices for Capricor Therapeutics' stock. Their forecasts range from $2.15 to $6.50. On average, they anticipate Capricor Therapeutics' stock price to reach $4.33 in the next twelve months. View Analyst Ratings for Capricor Therapeutics.
Are investors shorting Capricor Therapeutics?
Capricor Therapeutics saw a increase in short interest in October. As of October 13th, there was short interest totalling 1,577,570 shares, an increase of 26.5% from the September 29th total of 1,247,225 shares. Based on an average daily trading volume, of 3,845,022 shares, the days-to-cover ratio is currently 0.4 days. Approximately 14.0% of the company's stock are short sold.
Who are some of Capricor Therapeutics' key competitors?
Some companies that are related to Capricor Therapeutics include AcelRx Pharmaceuticals (ACRX), Galmed Pharmaceuticals (GLMD), Verona Pharma Plc (VRP), Zafgen (ZFGN), Gemphire Therapeutics (GEMP), Trevena (TRVN), ProQR Therapeutics (PRQR), Affimed N.V. (AFMD), Motif Bio plc (MTFB), Synthetic Biologics (SYN), Viking Therapeutics (VKTX), Bellerophon Therapeutics (BLPH), ADMA Biologics (ADMA), Nexvet Biopharma plc (NVET), MEI Pharma (MEIP), Lipocine (LPCN), Aeglea BioTherapeutics (AGLE) and Flex Pharma (FLKS).
Who are Capricor Therapeutics' key executives?
Capricor Therapeutics' management team includes the folowing people:
- Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
- Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
- Leland J. Gershell M.D. Ph.D., Chief Financial Officer, Principal Financial Officer (Age 44)
- Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
- Anthony Bergmann, Principal Accounting Officer, Vice President - Finance (Age 29)
- Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
- Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
- Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
- Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
- Deborah Ascheim M.D., Chief Medical Officer
Who owns Capricor Therapeutics stock?
Capricor Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Belpointe Asset Management LLC (0.32%), Jane Street Group LLC (0.25%) and Wells Fargo & Company MN (0.14%). Company insiders that own Capricor Therapeutics stock include Anthony Bergmann, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Institutional Ownership Trends for Capricor Therapeutics.
Who bought Capricor Therapeutics stock? Who is buying Capricor Therapeutics stock?
Capricor Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Belpointe Asset Management LLC, Jane Street Group LLC and Wells Fargo & Company MN. Company insiders that have bought Capricor Therapeutics stock in the last two years include Anthony Bergmann, Karen Krasney, Leland Gershell, Linda Marban, Louis J Grasmick, Louis Manzo and Sinai Medical Center Cedars. View Insider Buying and Selling for Capricor Therapeutics.
How do I buy Capricor Therapeutics stock?
Shares of Capricor Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Capricor Therapeutics' stock price today?
One share of Capricor Therapeutics stock can currently be purchased for approximately $2.10.
How big of a company is Capricor Therapeutics?
Capricor Therapeutics has a market capitalization of $53.99 million and generates $4 million in revenue each year. The biotechnology company earns $-18,800,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Capricor Therapeutics employs 40 workers across the globe.
How can I contact Capricor Therapeutics?
Capricor Therapeutics' mailing address is 8840 Wilshire Blvd Fl 2, BEVERLY HILLS, CA 90211-2606, United States. The biotechnology company can be reached via phone at +1-310-3583200 or via email at [email protected]
MarketBeat Community Rating for Capricor Therapeutics (CAPR)MarketBeat's community ratings are surveys of what our community members think about Capricor Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Capricor Therapeutics (NASDAQ:CAPR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$4.33 (105.95% upside)|
Consensus Price Target History for Capricor Therapeutics (NASDAQ:CAPR)
Analysts' Ratings History for Capricor Therapeutics (NASDAQ:CAPR)
(Data available from 11/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/15/2017||HC Wainwright||Boost Price Target||Buy -> Buy||$2.15 -> $6.50||N/A|
|7/22/2017||Rodman & Renshaw||Reiterated Rating||Buy||$2.15||N/A|
|10/20/2016||Roth Capital||Set Price Target||Buy||$12.00||N/A|
Earnings History and Estimates Chart for Capricor Therapeutics (NASDAQ:CAPR)
Earnings History by Quarter for Capricor Therapeutics (NASDAQ CAPR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/8/2017||Q3 2017||($0.19)||($0.12)||$1.00 million||$0.31 million||View||N/A|
|8/10/2017||Q2 2017||($0.18)||($0.16)||$1.10 million||$1.00 million||View||N/A|
|5/15/2017||Q1 2017||($0.15)||($0.17)||$0.87 million||$0.88 million||View||N/A|
|3/15/2017||Q4 2016||($0.30)||($0.14)||$1.05 million||$0.91 million||View||N/A|
|11/10/2016||Q316||($0.27)||($0.29)||$1.12 million||$0.75 million||View||N/A|
|8/15/2016||Q2||($0.24)||($0.26)||$1.22 million||$1.13 million||View||Listen|
|5/12/2016||Q116||($0.19)||($0.26)||$1.10 million||$1.22 million||View||Listen|
|3/17/2016||Q415||($0.19)||($0.21)||$1.10 million||$1.12 million||View||N/A|
|11/12/2015||Q315||($0.26)||($0.18)||$1.10 million||$1.32 million||View||N/A|
|8/13/2015||Q215||($0.26)||($0.19)||$1.10 million||$1.29 million||View||N/A|
|5/12/2015||Q1 2015||($0.14)||($0.23)||$1.10 million||$1.79 million||View||N/A|
|3/18/2015||Q4 2014||($0.14)||($0.16)||$1.30 million||$1.40 million||View||N/A|
|11/13/2014||Q3 2014||($0.22)||($0.13)||$1.30 million||View||N/A|
Earnings Estimates for Capricor Therapeutics (NASDAQ:CAPR)
Current Year EPS Consensus Estimate: $-0.7 EPS
Next Year EPS Consensus Estimate: $-0.76 EPS
Dividend History for Capricor Therapeutics (NASDAQ:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Capricor Therapeutics (NASDAQ CAPR)
Insider Ownership Percentage: 28.50%
Institutional Ownership Percentage: 3.09%
Insider Trades by Quarter for Capricor Therapeutics (NASDAQ CAPR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/9/2017||Louis Manzo||Director||Buy||10,000||$3.10||$31,000.00|| |
|5/9/2017||Sinai Medical Center Cedars||Major Shareholder||Buy||1,145,161||$3.10||$3,549,999.10|| |
|9/21/2016||Sinai Medical Center Cedars||Major Shareholder||Buy||312,500||$3.20||$1,000,000.00|| |
|3/16/2016||Anthony Bergmann||VP||Buy||2,030||$2.40||$4,872.00|| |
|3/16/2016||Karen Krasney||EVP||Buy||4,060||$2.40||$9,744.00|| |
|3/16/2016||Leland Gershell||CFO||Buy||2,100||$2.40||$5,040.00|| |
|3/16/2016||Linda Marban||CEO||Buy||10,152||$2.40||$24,364.80|| |
|3/16/2016||Louis J Grasmick||Director||Buy||91,369||$2.40||$219,285.60|| |
|3/16/2016||Sinai Medical Center Cedars||Major Shareholder||Buy||416,666||$2.40||$999,998.40|| |
|8/20/2015||Louis J. Grasmick||Director||Buy||11,900||$4.11||$48,909.00|| |
|8/19/2015||Eduardo Marban||major shareholder||Buy||18,400||$4.36||$80,224.00|| |
|1/21/2015||Joshua A Kazam||Director||Buy||7,096||$3.52||$24,977.92|| |
|1/21/2015||Sinai Medical Center Cedars||Major Shareholder||Buy||851,546||$3.52||$2,997,441.92|| |
Latest Headlines for Capricor Therapeutics (NASDAQ CAPR)
Capricor Therapeutics (NASDAQ CAPR) Chart for Wednesday, November, 22, 2017